REFERENCES
1. Flitcroft DI, He M, Jonas JB, et al. IMI - Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci 2019;60:M20-30.
2. Ohno-Matsui K, Wu PC, Yamashiro K, et al. IMI pathologic myopia. Invest Ophthalmol Vis Sci 2021;62:5.
3. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016;123:1036-42.
4. Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 2014;157:9-25.e12.
5. Grzybowski A, Kanclerz P, Tsubota K, Lanca C, Saw SM. A review on the epidemiology of myopia in school children worldwide. BMC Ophthalmol 2020;20:27.
6. Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology 2006;113:1134.e1-11.
7. Liang YB, Friedman DS, Wong TY, et al. Handan Eye Study Group. Prevalence and causes of low vision and blindness in a rural chinese adult population: the Handan Eye Study. Ophthalmology 2008;115:1965-72.
8. Jin ZB, Wu J, Huang XF, et al. Trio-based exome sequencing arrests de novo mutations in early-onset high myopia. Proc Natl Acad Sci U S A 2017;114:4219-24.
9. Cai XB, Shen SR, Chen DF, Zhang Q, Jin ZB. An overview of myopia genetics. Exp Eye Res 2019;188:107778.
10. Wang J, Li Y, Musch DC, et al. Progression of myopia in school-aged children after COVID-19 home confinement. JAMA Ophthalmol 2021;139:293-300.
11. Zhang X, Cheung SSL, Chan HN, et al. Myopia incidence and lifestyle changes among school children during the COVID-19 pandemic: a population-based prospective study. Br J Ophthalmol ;2021:bjophthalmol-2021.
12. Bullimore MA, Brennan NA. Myopia control: why each diopter matters. Optom Vis Sci 2019;96:463-5.
13. Xiao O, Guo X, Wang D, et al. Distribution and severity of myopic maculopathy among highly myopic eyes. Invest Ophthalmol Vis Sci 2018;59:4880-5.
14. Yan YN, Wang YX, Yang Y, et al. Ten-year progression of myopic maculopathy: the beijing eye study 2001-2011. Ophthalmology 2018;125:1253-63.
15. Fang Y, Yokoi T, Nagaoka N, et al. Progression of myopic maculopathy during 18-year follow-up. Ophthalmology 2018;125:863-77.
16. Koh V, Tan C, Tan PT, et al. Myopic Maculopathy and optic disc changes in highly myopic young asian eyes and impact on visual acuity. Am J Ophthalmol 2016;164:69-79.
17. Ohno-Matsui K, Kawasaki R, Jonas JB, et al. META-analysis for Pathologic Myopia (META-PM) Study Group. International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol 2015;159:877-83.e7.
18. Yan YN, Wang YX, Xu L, Xu J, Wei WB, Jonas JB. Fundus tessellation: prevalence and associated factors: the beijing eye study 2011. Ophthalmology 2015;122:1873-80.
19. Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 2010;117:1595-611, 1611.e1.
20. Ohno-Matsui K, Lai TY, Lai CC, Cheung CM. Updates of pathologic myopia. Prog Retin Eye Res 2016;52:156-87.
21. Wang NK, Lai CC, Chu HY, et al. Classification of early dry-type myopic maculopathy with macular choroidal thickness. Am J Ophthalmol 2012;153:669-77, 677.e1.
22. Jonas JB, Holbach L, Panda-Jonas S. Bruch’s membrane thickness in high myopia. Acta Ophthalmol 2014;92:e470-4.
23. Du R, Fang Y, Jonas JB, et al. Clinical features of patchy chorioretinal atrophy in pathologic myopia. Retina 2020;40:951-9.
24. Ohno-Matsui K, Jonas JB, Spaide RF. Macular bruch membrane holes in highly myopic patchy chorioretinal atrophy. Am J Ophthalmol 2016;166:22-8.
25. Jonas JB, Ohno-Matsui K, Spaide RF, Holbach L, Panda-Jonas S. Macular Bruch’s membrane defects and axial length: association with gamma zone and delta zone in peripapillary region. Invest Ophthalmol Vis Sci 2013;54:1295-302.
26. Yoshida T, Ohno-matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization. Ophthalmology 2003;110:1297-305.
27. Yokoi T, Ohno-Matsui K. Diagnosis and treatment of myopic maculopathy. Asia Pac J Ophthalmol (Phila) 2018;7:415-21.
28. Spaide RF. Choroidal neovascularization in younger patients. Curr Opin Ophthalmol 1999;10:177-81.
29. Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2003;87:570-3.
30. Ikuno Y, Jo Y, Hamasaki T, Tano Y. Ocular risk factors for choroidal neovascularization in pathologic myopia. Invest Ophthalmol Vis Sci 2010;51:3721-5.
31. Farinha CL, Baltar AS, Nunes SG, et al. Progression of myopic maculopathy after treatment of choroidal neovascularization. Ophthalmologica 2014;231:211-20.
32. Hayashi K, Ohno-Matsui K, Yoshida T, et al. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2005;243:13-9.
33. Yoshida T, Ohno-matsui K, Ohtake Y, et al. Long-term visual prognosis of choroidal neovascularization in high myopia. Ophthalmology 2002;109:712-9.
34. Nagaoka N, Shimada N, Hayashi W, et al. Characteristics of periconus choroidal neovascularization in pathologic myopia. Am J Ophthalmol 2011;152:420-427.e1.
35. Lee DH, Kang HG, Lee SC, Kim M. Features of optical coherence tomography predictive of choroidal neovascularisation treatment response in pathological myopia in association with fluorescein angiography. Br J Ophthalmol 2018;102:238-42.
36. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984;91:1573-81.
37. Kojima A, Ohno-Matsui K, Teramukai S, et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2006;244:1474-9.
39. Neelam K, Cheung CM, Ohno-Matsui K, Lai TY, Wong TY. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 2012;31:495-525.
40. Mcbrien N. Role of the sclera in the development and pathological complications of myopia. Progress in Retinal and Eye Research 2003;22:307-38.
41. Ohno-Matsui K, Akiba M, Ishibashi T, Moriyama M. Observations of vascular structures within and posterior to sclera in eyes with pathologic myopia by swept-source optical coherence tomography. Invest Ophthalmol Vis Sci 2012;53:7290-8.
42. Moriyama M, Ohno-Matsui K, Futagami S, et al. Morphology and long-term changes of choroidal vascular structure in highly myopic eyes with and without posterior staphyloma. Ophthalmology 2007;114:1755-62.
43. Ishida T, Watanabe T, Yokoi T, Shinohara K, Ohno-Matsui K. Possible connection of short posterior ciliary arteries to choroidal neovascularisations in eyes with pathologic myopia. Br J Ophthalmol 2019;103:457-62.
44. Xie J, Chen Q, Yu J, et al. Morphologic features of myopic choroidal neovascularization in pathologic myopia on swept-source optical coherence tomography. Front Med (Lausanne) 2020;7:615902.
45. Giuffrè C, Querques L, Carnevali A, De Vitis LA, Bandello F, Querques G. Choroidal neovascularization and coincident perforating scleral vessels in pathologic myopia. Eur J Ophthalmol 2017;27:e39-45.
46. Querques G, Corvi F, Balaratnasingam C, et al. Lacquer cracks and perforating scleral vessels in pathologic myopia: a possible causal relationship. Am J Ophthalmol 2015;160:759-66.e2.
47. Wakabayashi T, Ikuno Y, Oshima Y, Hamasaki T, Nishida K. Aqueous concentrations of vascular endothelial growth factor in eyes with high myopia with and without choroidal neovascularization. J Ophthalmol 2013;2013:257381.
49. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469-78.
50. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB j 1999;13:9-22.
51. Seko Y, Seko Y, Fujikura H, et al. Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci 1999;40:3287-91.
52. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in the aqueous humour in eyes with myopic choroidal neovascularization. Acta Ophthalmol 2011;89:459-62.
53. Costagliola C, Semeraro F, dell'Omo R, et al. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation. Br J Ophthalmol 2015;99:1004-8.
54. Ohno-Matsui K, Morita I, Tombran-Tink J, et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol 2001;189:323-33.
55. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A 2009;106:18751-6.
56. Shin Y. J, Nam W.H, Park S.E, Kim J.H, Kim H.K. Aqueous humor concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in high myopic patients. Mol Vis 2012;18:2265-70.
57. Chen W, Song H, Xie S, Han Q, Tang X, Chu Y. Correlation of macular choroidal thickness with concentrations of aqueous vascular endothelial growth factor in high myopia. Curr Eye Res 2015;40:307-13.
58. Yamamoto Y, Miyazaki D, Sasaki S, et al. Associations of inflammatory cytokines with choroidal neovascularization in highly myopic eyes. Retina 2015;35:344-50.
59. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009;284:6038-42.
60. Bianconi V, Sahebkar A, Atkin SL, Pirro M. The regulation and importance of monocyte chemoattractant protein-1. Curr Opin Hematol 2018;25:44-51.
61. Leveziel N, Yu Y, Reynolds R, et al. Genetic factors for choroidal neovascularization associated with high myopia. Invest Ophthalmol Vis Sci 2012;53:5004-9.
62. Dreismann AK, McClements ME, Barnard AR, et al. Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells. Gene Ther 2021;28:265-76.
63. Wang Q, Zhao HS, Li L. Association between complement factor I gene polymorphisms and the risk of age-related macular degeneration: a Meta-analysis of literature. Int J Ophthalmol 2016;9:298-305.
64. Fraczek LA, Martin BK. Transcriptional control of genes for soluble complement cascade regulatory proteins. Mol Immunol 2010;48:9-13.
65. Miyake M, Yamashiro K, Nakanishi H, et al. Evaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes. Invest Ophthalmol Vis Sci 2013;54:4208-12.
66. Steele FR, Chader GJ, Johnson LV, Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A 1993;90:1526-30.
67. Tombran-tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991;53:411-4.
68. Karakousis P. C, John S.K, Behling K.C, et al. Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol Vis 2001;7:154-63.
69. Tombran-tink J, Shivaram S, Chader G, Johnson L, Bok D. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. J Neurosci 1995;15:4992-5003.
70. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 2003;4:628-36.
71. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8.
72. Cayouette M, Smith SB, Becerra SP, Gravel C. Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations. Neurobiol Dis 1999;6:523-32.
73. Wang X, Liu X, Ren Y, et al. PEDF protects human retinal pigment epithelial cells against oxidative stress via upregulation of UCP2 expression. Mol Med Rep 2019;19:59-74.
74. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 2006;281:3604-13.
75. Renno R. Z, Youssri A.I, Michaud N, Gragoudas E.S, Miller J.W. Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2002;43:1574-80.
76. Ho TC, Yang YC, Cheng HC, Wu AC, Chen SL, Tsao YP. Pigment epithelium-derived factor protects retinal pigment epithelium from oxidant-mediated barrier dysfunction. Biochem Biophys Res Commun 2006;342:372-8.
77. Amano S, Yamagishi S, Inagaki Y, et al. Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes. Microvasc Res 2005;69:45-55.
78. Wang Y, Subramanian P, Shen D, Tuo J, Becerra SP, Chan CC. Pigment epithelium-derived factor reduces apoptosis and pro-inflammatory cytokine gene expression in a murine model of focal retinal degeneration. ASN Neuro 2013;5:e00126.
79. Ruiz-Medrano J, Montero JA, Flores-Moreno I, Arias L, García-Layana A, Ruiz-Moreno JM. Myopic maculopathy: current status and proposal for a new classification and grading system (ATN). Prog Retin Eye Res 2019;69:80-115.
80. Ruiz-Medrano J, Flores-Moreno I, Ohno-Matsui K, Cheung CMG, Silva R, Ruiz-Moreno JM. Correlation between atrophy-traction-neovascularization grade for myopic maculopathy and clinical severity. Retina 2021;41:1867-73.
81. Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia. Ophthalmology 2006;113:2285-91.
82. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology 2012;119:347-54.
83. Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol 2014;157:451-457.e1.
84. Chia A, Lu QS, Tan D. Five-Year Clinical Trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology 2016;123:391-9.
85. Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci 2012;53:7077-85.
86. Charm J, Cho P. High myopia-partial reduction ortho-k: a 2-year randomized study. Optom Vis Sci 2013;90:530-9.
87. Walline JJ, Jones LA, Sinnott LT. Corneal reshaping and myopia progression. Br J Ophthalmol 2009;93:1181-5.
88. Kakita T, Hiraoka T, Oshika T. Influence of overnight orthokeratology on axial elongation in childhood myopia. Invest Ophthalmol Vis Sci 2011;52:2170-4.
89. Zhu MJ, Feng HY, He XG, Zou HD, Zhu JF. The control effect of orthokeratology on axial length elongation in Chinese children with myopia. BMC Ophthalmol 2014;14:141.
90. Ng DSC, Fung NSK, Yip FLT, Lai TYY. Ranibizumab for myopic choroidal neovascularization. Expert Opin Biol Ther 2020;20:1385-93.
91. Zhang M, Zhang J, Yan M, et al. KH902 Phase 1 Study Group. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 2011;118:672-8.
92. Rudge JS, Holash J, Hylton D, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007;104:18363-70.
93. Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014;121:682-92.e2.
94. Chen C, Yan M, Huang Z, Song YP. The evaluation of a two-year outcome of intravitreal conbercept versus ranibizumab for pathological myopic choroidal neovascularization. Curr Eye Res 2020;45:1415-21.
95. Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome. Br J Ophthalmol 2013;97:1447-50.
96. Ng DSC, Ho M, Iu LPL, Lai TYY. Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. Expert Opin Drug Saf 2022;21:43-54.
97. Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology 2013;120:1944-5.e1.
98. Mitchell P, Holz FG, Hykin P, et al. ARIES study investigators. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the aries study: a randomized clinical trial. Retina 2021;41:1911-20.
99. Kim YC, Shin JP, Pak KY, et al. Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema. Sci Rep 2020;10:22030.
100. Hamilton RD, Clemens A, Minnella AM, et al. LUMINOUS study group. Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study. PLoS One 2020;15:e0227557.
101. Lai TY, Luk FO, Lee GK, Lam DS. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond) 2012;26:1004-11.
102. Cheung CMG, Arnold JJ, Holz FG, et al. Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology 2017;124:1690-711.
103. . Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. Ophthalmology 2001;108:841-52.
104. Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev 2005:CD004765.
105. Iwase T, Ueno Y, Ra E, Ito Y, Terasaki H. Changes in choriocapillaris and retinal morphology after laser photocoagulation by OCT angiography: A case report. Medicine (Baltimore) 2018;97:e13278.
106. Pece A, Brancato R, Avanza P, Camesasca F, Galli L. Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. Int Ophthalmol ;18:339-44.
107. Brancato R, Menchini U, Pece A, Capoferri C, Avanza P, Radrizzani E. Dye laser photocoagulation of macular subretinal neovascularization in pathological myopia. A randomized study of three different wavelengths. Int Ophthalmol 1988;11:235-8.
108. Secrétan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 1997;7:307-316.
109. Brancato R, Pece A, Avanza P, Radrizzani E. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia. Retina 1990;10:239-43.
110. Parodi M, La Spina C, Berchicci L, Petruzzi G, Bandello F. Photosensitizers and photodynamic therapy: Verteporfin. in: Nguyen Q, Rodrigues E, Farah M, Mieler W, Do D, editors. Retinal Pharmacotherapeutics. S. Karger AG :2015. pp. 330-6.
111. Schlötzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:748-57.
112. . Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia. Ophthalmology 2003;110:667-73.
113. Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003;87:173-6.
114. Kang HM, Koh HJ. Ocular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study. Retina 2013;33:1613-22.
115. Kim YM, Yoon JU, Koh HJ. The analysis of lacquer crack in the assessment of myopic choroidal neovascularization. Eye (Lond) 2011;25:937-46.
116. Zhu Y, Zhang T, Xu G, Peng L. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev 2016;12:CD011160.
117. MM Shevelev. Operation against high myopia and scleralectasia with aid of the transplantation of fascia lata on thinned sclera. Russian Oftalmol 1930;11:107-10.
118. WE B. , AA S. Surgical treatment of high myopia; the combined lamellar scleral resection with scleral reinforcement using donor eye. Trans Am Acad Ophthalmol 1958;62:791-802.
120. Nesterov AP, Libenson NB, Svirin AV. Early and late results of fascia lata transplantation in high myopia. Br J Ophthalmol 1976;60:271-2.
121. Chen M, Dai J, Chu R, Qian Y. The efficacy and safety of modified Snyder-Thompson posterior scleral reinforcement in extensive high myopia of Chinese children. Graefes Arch Clin Exp Ophthalmol 2013;251:2633-8.
122. Miao Z, Li L, Meng X, et al. Modified posterior scleral reinforcement as a treatment for high myopia in children and its therapeutic effect. Biomed Res Int 2019;2019:5185780.
123. Dong X, Liu J, Bu J. The efficacy of modified posterior scleral reinforcement with round scleral patches in Chinese children with high myopia. Graefes Arch Clin Exp Ophthalmol 2020;258:1543-7.
124. Xue A, Bao F, Zheng L, Wang Q, Cheng L, Qu J. Posterior scleral reinforcement on progressive high myopic young patients. Optom Vis Sci 2014;91:412-8.
125. Curtin B. J. The posterior staphyloma of pathologic myopia. Trans Am Ophthalmol Soc 1977;75:67-86.
126. Curtin BJ, Whitmore WG. Long-term results of scleral reinforcement surgery. Am J Ophthalmol 1987;103:544-8.
127. Wu H, Chen W, Zhao F, et al. Scleral hypoxia is a target for myopia control. Proc Natl Acad Sci U S A 2018;115:E7091-100.
128. Liu Y, Wang L, Xu Y, Pang Z, Mu G. The influence of the choroid on the onset and development of myopia: from perspectives of choroidal thickness and blood flow. Acta Ophthalmol 2021;99:730-8.
129. Nickla DL, Totonelly K. Choroidal thickness predicts ocular growth in normal chicks but not in eyes with experimentally altered growth. Clin Exp Optom 2015;98:564-70.
130. Zhou X, Zhang S, Zhang G, et al. Increased choroidal blood perfusion can inhibit form deprivation myopia in guinea pigs. Invest Ophthalmol Vis Sci 2020;61:25.
131. Zhang Z, Qi Y, Wei W, et al. Investigation of macular choroidal thickness and blood flow change by optical coherence tomography angiography after posterior scleral reinforcement. Front Med (Lausanne) 2021;8:658259.
132. Frisina R, Gius I, Palmieri M, Finzi A, Tozzi L, Parolini B. Myopic Traction Maculopathy: Diagnostic and management strategies. Clin Ophthalmol 2020;14:3699-708.
133. Ward B, Tarutta EP, Mayer MJ. The efficacy and safety of posterior pole buckles in the control of progressive high myopia. Eye (Lond) 2009;23:2169-74.
134. Liu B, Ma W, Li Y, et al. Macular buckling using a three-armed silicone capsule for foveoschisis associated with high myopia. Retina 2016;36:1919-26.
135. Alkabes M, Mateo C. Macular buckle technique in myopic traction maculopathy: a 16-year review of the literature and a comparison with vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2018;256:863-77.
136. Parolini B, Frisina R, Pinackatt S, et al. Indications and results of a new l-shaped macular buckle to support a posterior staphyloma in high myopia. Retina 2015;35:2469-82.
137. Liu B, Chen S, Li Y, et al. Comparison of macular buckling and vitrectomy for the treatment of macular schisis and associated macular detachment in high myopia: a randomized clinical trial. Acta Ophthalmol 2020;98:e266-72.
139. Wollensak G, Spoerl E. Collagen crosslinking of human and porcine sclera. J Cataract Refract Surg 2004;30:689-95.
140. Gawargious BA, Le A, Lesgart M, Ugradar S, Demer JL. Differential regional stiffening of sclera by collagen cross-linking. Curr Eye Res 2020;45:718-25.
141. Liu TX, Luo X, Gu YW, Yang B, Wang Z. Correlation of discoloration and biomechanical properties in porcine sclera induced by genipin. Int J Ophthalmol 2014;7:621-5.
142. Lin X, Naidu RK, Dai J, Zhou X, Qu X, Zhou H. Scleral cross-linking using glyceraldehyde for the prevention of axial elongation in the rabbit: blocked axial elongation and altered scleral microstructure. Curr Eye Res 2019;44:162-71.
143. Choi S, Lee SC, Lee HJ, et al. Structural response of human corneal and scleral tissues to collagen cross-linking treatment with riboflavin and ultraviolet A light. Lasers Med Sci 2013;28:1289-96.
144. Krasselt K, Frommelt C, Brunner R, Rauscher FG, Francke M, Körber N. Various cross-linking methods inhibit the collagenase I degradation of rabbit scleral tissue. BMC Ophthalmol 2020;20:488.
145. Wang M, Corpuz CC. Effects of scleral cross-linking using genipin on the process of form-deprivation myopia in the guinea pig: a randomized controlled experimental study. BMC Ophthalmol 2015;15:89.
146. Hannon BG, Luna C, Feola AJ, et al. Assessment of visual and retinal function following in vivo genipin-induced scleral crosslinking. Transl Vis Sci Technol 2020;9:8.
147. Sun M, Zhang F, Li Y, et al. Evaluation of the safety and long-term scleral biomechanical stability of UVA cross-linking on scleral collagen in rhesus monkeys. J Refract Surg 2020;36:696-702.
148. Xue A, Zheng L, Tan G, et al. Genipin-crosslinked donor sclera for posterior scleral contraction/reinforcement to fight progressive myopia. Invest Ophthalmol Vis Sci 2018;59:3564-73.
149. Weiss JN, Levy S. Stem cell ophthalmology treatment study (SCOTS): bone marrow derived stem cells in the treatment of Usher syndrome. Stem Cell Investig 2019;6:31.
150. Weiss JN, Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of Dominant Optic Atrophy. Stem Cell Investig 2019;6:41.
151. Weiss JN, Levy S, Benes SC. Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow-derived stem cells in the treatment of Leber's hereditary optic neuropathy. Neural Regen Res 2016;11:1685-94.
152. Weiss JN, Levy S, Benes SC. Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy. Neural Regen Res 2015;10:1507-15.
153. Weiss JN, Benes SC, Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment. Neural Regen Res 2016;11:1512-6.
154. Jonas JB, Cheung CMG, Panda-Jonas S. Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol (Phila) 2017;6:493-7.
155. Blasiak J. Senescence in the pathogenesis of age-related macular degeneration. Cell Mol Life Sci 2020;77:789-805.
156. Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet 2016;48:134-43.
157. Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K. Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci 2016;73:1765-86.
158. Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond) 2016;3:34.
159. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
160. Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches. Int J Mol Sci 2020;21:8242.
161. Tsang SH, Sharma T. Stargardt Disease. In: Tsang SH, Sharma T, editors. Atlas of inherited retinal diseases. Cham: Springer International Publishing; 2018. pp.139-51.
162. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open 2014;4:e004015.
163. Tsybovsky Y, Molday RS, Palczewski K. The ATP-Binding Cassette Transporter ABCA4: Structural and Functional Properties and Role in Retinal Disease. In: Lambris JD, Adamis AP, editors. Inflammation and retinal disease: complement biology and pathology. New York: Springer; 2010. pp. 105-25.
164. Zhang K, Kniazeva M, Han M, et al. A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. Nat Genet 2001;27:89-93.
165. Aveldaño MI. Phospholipid species containing long and very long polyenoic fatty acids remain with rhodopsin after hexane extraction of photoreceptor membranes. Biochemistry 1988;27:1229-39.
166. Suh M, Clandinin MT. 20:5n-3 but not 22:6n-3 is a preferred substrate for synthesis of n-3 very-long- chain fatty acids (C24-C36) in retina. Curr Eye Res 2005;30:959-68.
167. Norris CE, Keener JE, Perera SMDC, et al. Native mass spectrometry reveals the simultaneous binding of lipids and zinc to rhodopsin. Int J Mass Spectrom 2021;460:116477.
168. McMahon A, Jackson SN, Woods AS, Kedzierski W. A Stargardt disease-3 mutation in the mouse Elovl4 gene causes retinal deficiency of C32-C36 acyl phosphatidylcholines. FEBS Lett 2007;581:5459-63.
169. Kniazeva M, Chiang MF, Morgan B, et al. A new locus for autosomal dominant stargardt-like disease maps to chromosome 4. Am J Hum Genet 1999;64:1394-9.
170. Yang Z, Chen Y, Lillo C, et al. Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. J Clin Invest 2008;118:2908-16.
171. Stern J, Temple S. Retinal pigment epithelial cell proliferation. Exp Biol Med (Maywood) 2015;240:1079-86.
172. Zhang H, Su B, Jiao L, et al. Transplantation of GMP-grade human iPSC-derived retinal pigment epithelial cells in rodent model: the first pre-clinical study for safety and efficacy in China. Ann Transl Med 2021;9:245.
173. Schwartz SD, Hubschman J, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. The Lancet 2012;379:713-20.
174. Xiang P, Wu KC, Zhu Y, et al. A novel Bruch’s membrane-mimetic electrospun substrate scaffold for human retinal pigment epithelium cells. Biomaterials 2014;35:9777-88.
175. Diniz B, Thomas P, Thomas B, et al. Subretinal implantation of retinal pigment epithelial cells derived from human embryonic stem cells: improved survival when implanted as a monolayer. Invest Ophthalmol Vis Sci 2013;54:5087-96.
176. da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol 2018;36:328-37.
177. Kashani AH, Lebkowski JS, Rahhal FM, et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Transl Med 2018;10:eaao4097.
178. Mandai M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med 2017;376:1038-46.
179. Zhang CJ, Ma Y, Jin ZB. The road to restore vision with photoreceptor regeneration. Exp Eye Res 2021;202:108283.
180. Golchin A, Farahany TZ. Biological products: cellular therapy and FDA approved products. Stem Cell Rev Rep 2019;15:166-75.
181. Zhang Z, Wei Y, Jiang X, Zhang S. Pars plana vitrectomy and wide internal limiting membrane peeling with perfluoropropane tamponade for highly myopic foveoschisis-associated macular hole. Retina 2017;37:274-82.
182. Shao Q, Xia H, Heussen FM, Ouyang Y, Sun X, Fan Y. Postoperative anatomical and functional outcomes of different stages of high myopia macular hole. BMC Ophthalmol 2015;15:93.
183. Qu J, Zhao M, Jiang Y, Li X. Vitrectomy outcomes in eyes with high myopic macular hole without retinal detachment. Retina 2012;32:275-80.
184. Fang Y, Yokoi T, Shimada N, et al. Development of macular atrophy after pars plana vitrectomy for myopic traction maculopathy and macular hole retinal detachment in pathologic myopia. Retina 2020;40:1881-93.
185. Alkabes M, Pichi F, Nucci P, et al. Anatomical and visual outcomes in high myopic macular hole (HM-MH) without retinal detachment: a review. Graefes Arch Clin Exp Ophthalmol 2014;252:191-9.
186. Pang CE, Sarraf D, Freund KB. Extreme choroidal thinning in high myopia. Retina 2015;35:407-15.
187. Keeley F, Morin J, Vesely S. Characterization of collagen from normal human sclera. Exp Eye Res 1984;39:533-42.
188. Boote C, Sigal IA, Grytz R, Hua Y, Nguyen TD, Girard MJA. Scleral structure and biomechanics. Prog Retin Eye Res 2020;74:100773.
190. Shen L, You QS, Xu X, et al. Scleral and choroidal volume in relation to axial length in infants with retinoblastoma versus adults with malignant melanomas or end-stage glaucoma. Graefes Arch Clin Exp Ophthalmol 2016;254:1779-86.
191. Curtin BJ, Iwamoto T, Renaldo DP. Normal and staphylomatous sclera of high myopia. An electron microscopic study. Arch Ophthalmol 1979;97:912-5.
192. Guggenheim J. A, McBrien N.A. Form-deprivation myopia induces activation of scleral matrix metalloproteinase-2 in tree shrew. Invest Ophthalmol Vis Sci 1996;37:1380-95.
193. Rada J. A, Nickla D.L, Troilo D. Decreased proteoglycan synthesis associated with form deprivation myopia in mature primate eyes. Invest Ophthalmol Vis Sci ;41:2050-8.
194. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003;200:500-3.
195. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell 2001;12:2730-41.
196. Jobling AI, Gentle A, Metlapally R, McGowan BJ, McBrien NA. Regulation of scleral cell contraction by transforming growth factor-beta and stress: competing roles in myopic eye growth. J Biol Chem 2009;284:2072-9.
197. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349-63.
198. Shinohara K, Yoshida T, Liu H, et al. Establishment of novel therapy to reduce progression of myopia in rats with experimental myopia by fibroblast transplantation on sclera. J Tissue Eng Regen Med 2018;12:e451-61.
199. Tsai CL, Wu PC, Fini ME, Shi S. Identification of multipotent stem/progenitor cells in murine sclera. Invest Ophthalmol Vis Sci 2011;52:5481-7.
200. Zvaifler NJ, Marinova-Mutafchieva L, Adams G, et al. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res 2000;2:477-88.
201. Nakahara H. In vitro differentiation of bone and hypertrophic cartilage from periosteal-derived cells*1. Exp Cell Res 1991;195:492-503.
202. Čamernik K, Marc J, Zupan J. Human skeletal muscle-derived mesenchymal stem/stromal cell isolation and growth kinetics analysis. In: Turksen K, editor. Stem Cells and Aging. New York: Springer; 2019. pp. 119-29.
203. Friedenstein A. J., Gorskaja J.F., Kulagina N.N. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976;4:267-74. [PMID:976387.
204. Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A 2000;97:13625-30.
205. Wang L, Huang S, Li S, et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study. Drug Des Devel Ther 2019;13:4331-40.
206. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003;102:1548-9.
207. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004;22:1338-45.
208. Motaln H, Schichor C, Lah TT. Human mesenchymal stem cells and their use in cell-based therapies. Cancer 2010;116:2519-30.
209. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821-7.
210. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22.
211. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367-72.
212. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005;105:2214-9.
213. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006;98:1076-84.
214. Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009;20:419-27.
215. Kinnaird T, Stabile E, Burnett MS, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004;109:1543-9.
216. Seah I, Liu Z, Soo Lin Wong D, et al. Retinal pigment epithelium transplantation in a non-human primate model for degenerative retinal diseases. J Vis Exp 2021; doi: 10.3791/62638.
217. Li XJ, Yang XP, Li QM, et al. Posterior scleral reinforcement for the treatment of pathological myopia. Int J Ophthalmol 2016;9:580-4.
218. Peng C, Xu J, Ding X, et al. Effects of posterior scleral reinforcement in pathological myopia: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol 2019;257:607-17.
219. Shen ZM, Zhang ZY, Zhang LY, Li ZG, Chu RY. Posterior scleral reinforcement combined with patching therapy for pre-school children with unilateral high myopia. Graefes Arch Clin Exp Ophthalmol 2015;253:1391-5.
